X
[{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$37.2 million","upfrontCash":"Undisclosed","newsHeadline":"OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"KB Investment","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces Positive Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
OLX10010 is an asymmetric siRNA duplex with a cell-penetrating moiety attached to the 3’ of sense strand (cell-penetrating asymmetric siRNA, i.e. cp-asiRNA), targeting human connective tissue growth factor, which is a key factor in the development of hypertrophic scars.
Lead Product(s):
OLX10010
Therapeutic Area: Dermatology
Product Name: OLX101A
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 28, 2023
Details:
OLX10010 (compound name of OLX101A), a drug that targets connective tissue growth factor, is in phase 2 development as a treatment for hypertrophic scar.
Lead Product(s):
OLX10010
Therapeutic Area: Dermatology
Product Name: OLX101A
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 07, 2022
Details:
The capital will be used to finance R&D activities. The Company’s dry and wet AMD (OLX301A/OLX10010) and androgenic alopecia (OLX104C) programs are also planned to be entered into clinical trials, followed by HBV (OLX703A) and nonalcoholic steatohepatitis (OLX702A).
Lead Product(s):
OLX10010
Therapeutic Area: Dermatology
Product Name: OLX101A
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
KB Investment
Deal Size: $45.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
May 27, 2022
Details:
Capital will fund construction of RNA synthesis GMP facility in San Diego to advance the company’s core pipeline, including OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis.
Lead Product(s):
OLX101A
Therapeutic Area: Dermatology
Product Name: OLX101A
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $37.2 million
Upfront Cash: Undisclosed
Deal Type: Financing
December 01, 2020